Brandt, SD; Kavanagh, PV. Addressing the challenges in forensic drug chemistry. Drug Test. Analysis, 1 Mar 2017, 9 (3), 342-346. 120 kB. https://doi.org/10.1002/dta.2169
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
McLaughlin, G; Baumann, MH; Kavanagh, PV; Morris, N; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Hessman, G; Westphal, F; Walther, D; Brandt, SD. Synthesis, analytical characterization and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta-positional isomers. Drug Test. Analysis, 1 Sep 2018, 10 (9), 1404-1416. 20.6 MB. https://doi.org/10.1002/dta.2396 #3-FPM
Mardal, M; Miserez, B; Bade, R; Portolés, T; Bischoff, M; Hernández, F; Meyer, MR. 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. J. Pharm. Biomed. Anal., 1 Sep 2016, 128 485–495. 651 kB. https://doi.org/10.1016/j.jpba.2016.06.011 #3-Fluorophenmetrazine
Grumann, C; Huppertz, LM; Bisel, P; Angerer, V; Auwärter, V. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug Test. Analysis, 19 Feb 2019, n/a. 555 kB. https://doi.org/10.1002/dta.2577 #3-FPM
Mayer, FP; Burchardt, NV; Decker, AM; Partilla, JS; Li, Y; McLaughlin, G; Kavanagh, PV; Sandtner, W; Blough, BE; Brandt, SD; Baumann, MH; Sitte, HH. Fluorinated phenmetrazine “legal highs” act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology, 6 Oct 2017, n/a. 1.2 MB. https://doi.org/10.1016/j.neuropharm.2017.10.006 #3-FPM
Chapman, SJ. Novel Psychoactive Spectra: NMR of (mostly) Novel Psychoactive Substances. BLOTTER, 25 Jun 2018, 3 (2). https://doi.org/10.16889/isomerdesign-6 #3-FPM Open access DOI NMR